DGAP-Adhoc: PAION AG GRANTS LICENSE TO YICHANG HUMANWELL

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Sep 24, 2014 at 4:45 AM

DGAP-Adhoc: PAION AG GRANTS LICENSE TO YICHANG HUMANWELL FOR M6G IN CHINA

PAION AG / Key word(s): Contract 24.09.2014 10:33 Dissemination of an Ad hoc announcement according to Â§ 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- PAION AG GRANTS LICENSE TO YICHANG HUMANWELL FOR M6G IN CHINA - EUR 1.6 million license fee - first payment of EUR 0.8 million due upon signing of the agreement Aachen (Germany), 24 September 2014 - PAION AG, a Specialty Pharma Company (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) and Yichang Humanwell Pharmaceutical Co. Ltd, China, today announced that they have entered into a license agreement for M6G which gives Yichang an exclusive licence under PAION's know-how regarding M6G for the development, manufacture and commercialization in the territory of People's Republic of China. By concluding the license PAION receives payments totalling EUR 1.6 million. EUR 0.8 million is due through today's signing of the license agreement. The remaining payments are due upon reaching certain development milestones in the next 1.5 years. Yichang intends to develop and commercialize M6G for peri-operative pain for the Chinese Market. --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: About PAION PAION AG is a publicly-listed Specialty Pharma Company headquartered in Aachen, Germany with a second site in Cambridge, UK. The company has a track record in developing and out licensing of hospital-based treatments for which there is substantial unmet medical need. PAION's strategy is to extend its business model from a pure development company to a specialty pharmaceutical company with a focus on anaesthesia products. Remimazolam is intended to be the basis for its future marketing activities. About YICHANG Yichang Humanwell Pharmaceutical Co. is part of Wuhan Humanwell healthcare (Group) Co., Ltd an industrial group giving priority to the medical health business, specializes in the development, production, distribution and technical support of pharmaceutical, medical instruments and reproductive healthcare products and technologies. Yichang Humanwell is the largest company to develop and produce narcotic products in China. About M6G Morphine-6-glucuronide (M6G) is an active potent metabolite of morphine which may offer therapeutic advantages over morphine, the current gold standard for the treatment of moderate to severe post-operative pain, in having an equivalent analgesic effect, but with a reduced potential to cause side-effects such as nausea and vomiting. Clinical trials have shown that M6G given intravenously can induce analgesia equivalent to morphine in the treatment of moderate to severe post-operative pain. These studies, along with those published in the scientific literature, suggest that M6G also induces less post operative nausea and vomiting compared with morphine, as well as less sedation and respiratory depression. Two Phase III trials have been completed with M6G. M6G has the potential to be a good fit in PAION's anaesthesia portfolio. Contact Ralf Penner Director Investor Relations / Public Relations PAION AG Martinstrasse 10-12 52062 Aachen - Germany Phone: +49 241 4453-152 E-mail: r.penner@paion.com www.paion.com Disclaimer: This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments. 24.09.2014 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: PAION AG Martinstr. 10-12 52062 Aachen Germany Phone: +49 (0)241-4453-0 Fax: +49 (0)241-4453-100 E-mail: info@paion.com Internet: www.paion.com ISIN: DE000A0B65S3 WKN: A0B65S Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, DÃ¼sseldorf, Hamburg, MÃ¼nchen, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sirha Lyon® 2027: A New Chapter in Foodservice

A Bold Step Forward There's a hearty aroma wafting from Lyon this January, and it's not just from the local gastronomy. Sirha Lyon® is queuing up for its 23rd edition, promising to turn the Foodservice and Hospitality sectors on their heads. Nearly 150,000 square meters of exhibition space packed to the rafters with over 4,300 exhibitors—this ain't your average trade...

UFP Industries Fortifies Gulf Coast with $27M Buy

UFP Industries Makes a Strategic Move Folks, it looks like UFP Industries (NASDAQ: UFPI) is making some solid moves down in the Gulf Coast, and they're shelling out $27 million to do it. This time, they've got their eyes on Apache Products, dba Acme Skid, a company that's been doing the heavy lifting in the pallet manufacturing space in Silsbee, Texas. Apparently, these...

New Drug Revolutionizes Endometrial Cancer Treatment

A New Dawn for Endometrial Cancer Treatment Alright, every once in a while, something shakes up the world of oncology. And that's exactly what's happening with sacituzumab tirumotecan, or sac-TMT if you want to save your breath. This new drug is stepping up as a future star in the fight against endometrial cancer, according to an eye-popping international study led by NYU...

Shure Leads AI-Enabled Smart Hardware for Hybrid Meetings

Shure's Leap into AI-Powered Hybrid Meetings It’s not every day you hear about an old-school audio company leading the charge in AI technology, yet here we have Shure, flexing its muscles in the IDC MarketScape for AI-enabled conference gear. This move isn't just a head-nod to their century-plus in audio; it's them steelin' up for the modern hybrid work battlefield....

Noble's Q3 2026: A Mixed Bag of Contracts & Losses

Noble's Third Quarter: Riding Choppy Waters Sometimes you're up, sometimes you're drowning in red ink. Noble Corporation seemed to catch a bit of both waves this quarter. Contracts: A Silver Lining? The markets felt a jolt with Noble pulling in roughly $560 million in new contracts since July. Not too shabby for a company trying to navigate the muddy waters of today's...

OperaWine 2027 Spotlights Women-Led Italian Wineries

The Rise of Women's Leadership in Italian Winemaking If there’s anything that gets me up off the bench, it’s innovation in tradition. And that's just what Vinitaly OperaWine is doing in 2027. For the first time, they've carved out a special category, "Led by Women," featuring a lineup of 46 Italian wineries ran by women. These ladies are stepping into the limelight at...

Post University Expands with New Tech and Health Degrees

If you're looking to invest in an education with promising payoffs, you might look into what's cooking over at Post University. They've just dropped a bombshell of new programs sure to get some attention from tech heads and health nuts alike, and I can't help but think there's potential brewing here. New Academic Paths Emerge Post University isn't resting on its...

Essential Oils Market Booms; Hits $29.52Bn by 2031

Essential Oils: Aromatherapy's New Frontier and Pharma Ally What’s the deal with essential oils? Well, it seems they’re not just for your neighbor’s pricey diffuser anymore. According to some fresh numbers, we're staring down a market worth nearly $30 billion by 2031. And it ain't all incense and hippie stores fueling this beast — we're talking a serious expansion...

Brennan Takes a Swing: Barrasso Endorsement in Hand

Brennan Shakes Up Wyoming Politics You don’t need a crystal ball to see the chess game unfolding in Wyoming's political landscape. Shannon Brennan's bid for the House seat in Teton County's District 23 got a heavy artillery boost today. She’s landed the endorsement of Senator John Barrasso, none other than the Senate Majority Whip and a formidable player in the Senate...

DIRECTV and DAZN: NBA Games Reach Local Fans

DIRECTV Teams Up With DAZN: A Slam Dunk for NBA Fans DIRECTV just inked a deal with DAZN to broadcast games for five NBA teams—Cleveland Cavaliers, Indiana Pacers, Memphis Grizzlies, Minnesota Timberwolves, and San Antonio Spurs—across their territories. For fans, this means a whole lot more hoops action conveniently bundled into your TV package, right in your living...